Back to search

BIOTEK2021-Bioteknologi for verdiskaping

NordPerMed: PERAID - Personalized Medicine in Acute Infectious Diseases

Alternative title: Personbasert medisin i akutt infeksjonssykdom

Awarded: NOK 10.0 mill.

In personalized medicine, unique medical information about a person?s genes, proteins, and environmental factors are utilized to improve quality of diagnosis and disease treatment down to case level. In the present project, PERAID, we propose to implement personalized medicine in severe infectious diseases. We will specifically focus on the large heterogeneous group of patients with sepsis, that represents a global health priority. The patient population is highly heterogeneous with different infections, caused by a wide range of microbes as etiologic pathogens. The pathogenic mechanisms of the infections causing sepsis vary widely, e.g. predisposing host factors influence host? responses to infection. One cause of sepsis is the life-threatening necrotizing soft tissue infections (NSTIs), in the public often referred to as flesh eating infection. In sepsis, and also in NSTI causing sepsis, this response is dysregulated. The response is associated to severity, organ failure, and outcome. In this patient group therefore, tailored immunotherapy holds great potential. We are currently investigating potential biomarkers to improve stratification of patients, we are enrolling sepsis patients prospectively to validate stratification strategies and we are presently designing small scale treatment studies, aiming at improving patient outcome in serious infections with high morbidity and mortality.

The PERAID project proposes to implement personalized medicine (PM) in severe infectious diseases, specifically focusing on the life-threatening necrotizing soft tissue infections (NSTI) as well as the large heterogeneous group of sepsis patients that represent a global health priority. Personalized medicine is a neglected, albeit much desired, development in the field of acute infectious diseases. The patient population is highly heterogeneous with different pathogens, pathogenic mechanisms, as well as varying predisposing host factors, and importantly, a dysregulated host response to infection is directly linked to severity and outcome of severe infections, i.e. sepsis and NSTI. Hence, tailored immunotherapy in stratified patients holds great potential. PERAID builds on the advances and resources created in the EU FP7-project INFECT, including the world’s largest patient cohort on NSTI (Scandinavian patients enrolled by PERAID’s partners), biobank, multi-omics data, and pathophysiologic models. These already available resources combined with an extended Nordic consortium enables PERAID to advance to the next phase of implementing PM in NSTI as well as extending the efforts into the sepsis field.

Publications from Cristin

No publications found

No publications found

No publications found

No publications found

Funding scheme:

BIOTEK2021-Bioteknologi for verdiskaping